279 related articles for article (PubMed ID: 29088109)
1. Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality.
Pircher A; Wolf D; Heidenreich A; Hilbe W; Pichler R; Heidegger I
Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29088109
[TBL] [Abstract][Full Text] [Related]
2. The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer.
Ren S; Xiong X; You H; Shen J; Zhou P
Front Immunol; 2021; 12():689132. PubMed ID: 34149730
[TBL] [Abstract][Full Text] [Related]
3. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.
Rini BI; McDermott DF; Hammers H; Bro W; Bukowski RM; Faba B; Faba J; Figlin RA; Hutson T; Jonasch E; Joseph RW; Leibovich BC; Olencki T; Pantuck AJ; Quinn DI; Seery V; Voss MH; Wood CG; Wood LS; Atkins MB
J Immunother Cancer; 2016; 4():81. PubMed ID: 27891227
[TBL] [Abstract][Full Text] [Related]
4. Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy.
Bang A; Wilhite TJ; Pike LRG; Cagney DN; Aizer AA; Taylor A; Spektor A; Krishnan M; Ott PA; Balboni TA; Hodi FS; Schoenfeld JD
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):344-351. PubMed ID: 28463153
[TBL] [Abstract][Full Text] [Related]
5. The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.
Manegold C; Dingemans AC; Gray JE; Nakagawa K; Nicolson M; Peters S; Reck M; Wu YL; Brustugun OT; Crinò L; Felip E; Fennell D; Garrido P; Huber RM; Marabelle A; Moniuszko M; Mornex F; Novello S; Papotti M; Pérol M; Smit EF; Syrigos K; van Meerbeeck JP; van Zandwijk N; Yang JC; Zhou C; Vokes E
J Thorac Oncol; 2017 Feb; 12(2):194-207. PubMed ID: 27729297
[TBL] [Abstract][Full Text] [Related]
6. Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents.
Puri S; Chatwal M; Gray JE
Expert Rev Respir Med; 2017 Oct; 11(10):791-805. PubMed ID: 28786318
[TBL] [Abstract][Full Text] [Related]
7. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer.
Santana-Davila R; Chow LQ
Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785
[No Abstract] [Full Text] [Related]
8. Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma.
Li X; Xu P; Wang C; Xu N; Xu A; Xu Y; Sadahira T; Araki M; Wada K; Matsuura E; Watanabe M; Zheng J; Sun P; Huang P; Nasu Y; Liu C
Oncotarget; 2017 Mar; 8(13):21177-21186. PubMed ID: 28416753
[TBL] [Abstract][Full Text] [Related]
9. Immune therapy for kidney cancer: a second dawn?
McDermott DF; Atkins MB
Semin Oncol; 2013 Aug; 40(4):492-8. PubMed ID: 23972713
[TBL] [Abstract][Full Text] [Related]
10. Emerging therapeutic agents for advanced non-small cell lung cancer.
Chen R; Manochakian R; James L; Azzouqa AG; Shi H; Zhang Y; Zhao Y; Zhou K; Lou Y
J Hematol Oncol; 2020 May; 13(1):58. PubMed ID: 32448366
[TBL] [Abstract][Full Text] [Related]
11. Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?
Rassy E; Mezquita L; Remon J; Besse B
Immunotherapy; 2019 Sep; 11(13):1149-1160. PubMed ID: 31361172
[TBL] [Abstract][Full Text] [Related]
12. [Research Progress of Anti-angiogenic Agents Combined with Immunotherapy
in Patients with Advanced Non-small Cell Lung Cancer].
Wang J; Peng W; Jiang M; Wu L
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):196-203. PubMed ID: 33819970
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials.
Godwin JL; Zibelman M; Plimack ER; Geynisman DM
Discov Med; 2014 Dec; 18(101):341-50. PubMed ID: 25549705
[TBL] [Abstract][Full Text] [Related]
14. Novel immunotherapeutic strategies in development for renal cell carcinoma.
Inman BA; Harrison MR; George DJ
Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapy in renal cell carcinoma.
Gul A; Rini BI
Cancer; 2019 Sep; 125(17):2935-2944. PubMed ID: 31225907
[TBL] [Abstract][Full Text] [Related]
16. Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer.
Daly ME; Monjazeb AM; Kelly K
J Thorac Oncol; 2015 Dec; 10(12):1685-93. PubMed ID: 26484629
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis inhibition in non-small cell lung cancer: a critical appraisal, basic concepts and updates from American Society for Clinical Oncology 2019.
Cantelmo AR; Dejos C; Kocher F; Hilbe W; Wolf D; Pircher A
Curr Opin Oncol; 2020 Jan; 32(1):44-53. PubMed ID: 31609741
[TBL] [Abstract][Full Text] [Related]
18. [Not Available].
Vano YA; Simonaggio A; Thibault C; Oudard S
Bull Cancer; 2018 Dec; 105 Suppl 1():S24-S34. PubMed ID: 30595195
[TBL] [Abstract][Full Text] [Related]
19. Recent clinical trials of immunotherapy in non-small-cell lung cancer.
Gkolfinopoulos S; Mountzios G
Immunotherapy; 2019 Apr; 11(6):461-466. PubMed ID: 30860438
[No Abstract] [Full Text] [Related]
20. [Immunotherapies and targeted therapies in medical oncology].
Rousseau B; Champiat S; Loirat D; Arrondeau J; Lemoine N; Soria JC
Bull Cancer; 2014 Jan; 101(1):31-9. PubMed ID: 24333964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
